SARCOMA TREATMENT MARKET ANALYSIS
Key players are focusing on enhancing their product portfolio through product launches and new product approvals for sarcoma treatment. For instance, in January 2020, Epizyme, Inc., received the U.S. Food and Drug Administration (FDA) approval for Tazverik, a target specific drug indicated for the treatment of epithelioid sarcoma in patients of age 16 and above.
Furthermore, players operating in the market are focused on research for development of new and efficient treatment for sarcoma. For instance, in October 2019, Tyme Technologies, Inc. initiated HopES, a phase 2 clinical trial, to evaluate safety and efficacy of SM-88, a monotherapy for clinically advanced sarcomas. The trial is expected to complete in the year 2022.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
